On the heels of disappointing low-dose data results, Zealand Pharma is back with separate findings for its GLP-1/GLP-2 ...

One of the biopharma industry’s marvels of the 2020s has been the enormous medical and financial success of the GLP-1 class ...

Among these, incretin-modulating treatments—whether used alone or in combination—are expected to play a pivotal role in shaping the future of MASH management. "GLP-1 therapies: a new frontier ...

The first thing that I consider relevant to clarify it is that both GLP-1 and GIP are the two most important incretin hormones in our system. Incretins are hormones produced by cells located in ...

There are, in fact, many different types of GLP-1 agonist drugs. Sometimes referred to as "incretin mimetics", as they interfere with this appetite controlling hormone's receptors, making us feel ...

Roche has reported early-stage clinical data with an oral GLP-1 agonist acquired as part of ... were "consistent with the safety profile of the incretin drug class," and will now progress to ...

Objective The incretins glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) account for up to 60% of postprandial insulin release in healthy people. Previous ...

The emergence of incretin-modulating therapies has transformed the way healthcare ... This distinction may explain why GLP-1/GIP agonists are more effective for T2D than for MASH, making ...